A detailed history of Walleye Capital LLC transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Walleye Capital LLC holds 1,400 shares of NBIX stock, worth $189,587. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,400
Previous 6,100 77.05%
Holding current value
$189,587
Previous $839,000 80.81%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$114.58 - $153.15 $9.57 Million - $12.8 Million
83,559 Added 1821.65%
88,146 $10.1 Million
Q2 2024

Aug 14, 2024

BUY
$130.86 - $143.19 $528,281 - $578,058
4,037 Added 734.0%
4,587 $631,000
Q1 2024

May 15, 2024

BUY
$130.4 - $143.74 $71,720 - $79,057
550 New
550 $75,000
Q3 2023

Nov 14, 2023

BUY
$94.02 - $117.1 $2.89 Million - $3.6 Million
30,713 New
30,713 $3.46 Million
Q1 2023

May 15, 2023

BUY
$94.11 - $123.02 $1.43 Million - $1.87 Million
15,161 New
15,161 $1.53 Million
Q2 2022

Aug 08, 2022

SELL
$75.79 - $100.07 $1.94 Million - $2.56 Million
-25,533 Closed
0 $0
Q1 2022

May 16, 2022

SELL
$72.45 - $94.81 $206,410 - $270,113
-2,849 Reduced 10.04%
25,533 $2.39 Million
Q4 2021

Mar 03, 2022

BUY
$79.65 - $106.22 $1.96 Million - $2.61 Million
24,582 Added 646.89%
28,382 $2.42 Million
Q3 2021

Nov 15, 2021

SELL
$86.18 - $99.03 $360,835 - $414,638
-4,187 Reduced 52.42%
3,800 $364,000
Q2 2021

Aug 16, 2021

BUY
$89.43 - $102.27 $714,277 - $816,830
7,987 New
7,987 $777,000
Q2 2020

Aug 14, 2020

SELL
$85.09 - $130.36 $147,546 - $226,044
-1,734 Closed
0 $0
Q1 2020

May 15, 2020

SELL
$75.11 - $113.76 $532,830 - $807,013
-7,094 Reduced 80.36%
1,734 $150,000
Q4 2019

Feb 14, 2020

BUY
$86.8 - $118.57 $537,378 - $734,066
6,191 Added 234.77%
8,828 $949,000
Q3 2019

Nov 14, 2019

BUY
$83.82 - $101.5 $221,033 - $267,655
2,637 New
2,637 $238,000

Others Institutions Holding NBIX

About NEUROCRINE BIOSCIENCES INC


  • Ticker NBIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 95,639,296
  • Market Cap $13B
  • Description
  • Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...
More about NBIX
Track This Portfolio

Track Walleye Capital LLC Portfolio

Follow Walleye Capital LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Walleye Capital LLC, based on Form 13F filings with the SEC.

News

Stay updated on Walleye Capital LLC with notifications on news.